CTOs on the Move

Visus Therapeutics

www.visustx.com

 
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion
  • www.visustx.com
  • 2 Nickerson Street Suite 101
    Seattle, WA USA 98109
  • Phone: 800.281.4536

Executives

Name Title Contact Details

Funding

Visus Therapeutics raised $36M on 03/09/2021

Similar Companies

Crucell Biologics

Crucell N.V. (Crucell) is a biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. Crucell product candidates include flu-mAb, an antibody product effective against a range of

OutcomesMTM

OutcomesMTM is a West Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TransTech Pharma

TransTech Pharma is a High Point, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nova-Tech Engineering Inc

Nova-Tech Engineering Inc is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sollis Therapeutics

Sollis Therapeutics is a privately held pharmaceutical company developing non-opioid analgesic products. Our first product is a long acting formulation of a compound with both analgesic and anti-inflammatory properties this combination is perfectly tailored to the treatment of severe neuropathic pain conditions such as sciatica.